• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Contineum Therapeutics, Inc. - Common stock (NQ:CTNM)

    14.61 +0.42 (+2.96%)
    Streaming Delayed Price Updated: 1:16 PM EDT, Aug 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,810,326
    Open 14.15
    Bid (Size) 14.57 (500)
    Ask (Size) 14.67 (800)
    Prev. Close 14.19
    Today's Range 14.15 - 15.15
    52wk Range 7.260 - 16.91
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    These stocks are moving in today's pre-market session ↗
    Via Chartmill
    News headline image
    Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
    From Contineum Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    +28.3%
    +28.3%
    1 Month
    +2.7%
    +2.7%
    3 Month
    +13.6%
    +13.6%
    6 Month
    -0.5%
    -0.5%
    1 Year
    +80.4%
    +80.4%

    More News

    Read More
    News headline image
    Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry
    From Contineum Therapeutics, Inc.
    Via Business Wire
    Contineum Therapeutics (NASDAQ:CTNM) Reports Q4 2025 Loss, Highlights Clinical Progress and Extended Cash Runway ↗
    Via Chartmill
    News headline image
    Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential ↗
    Via MarketBeat
    News headline image
    Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Announces Proposed $75.0 Million Public Offering
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference
    From Contineum Therapeutics
    Via Business Wire
    News headline image
    Get insights into the top gainers and losers of Thursday's after-hours session. ↗
    Via Chartmill
    News headline image
    Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
    From Contineum Therapeutics, Inc.
    Via Business Wire
    News headline image
    This Lululemon Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday ↗
    Via Benzinga
    News headline image
    This Biogen Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
    Via Benzinga

    Frequently Asked Questions

    Is Contineum Therapeutics, Inc. - Common stock publicly traded?
    Yes, Contineum Therapeutics, Inc. - Common stock is publicly traded.
    What exchange does Contineum Therapeutics, Inc. - Common stock trade on?
    Contineum Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Contineum Therapeutics, Inc. - Common stock?
    The ticker symbol for Contineum Therapeutics, Inc. - Common stock is CTNM on the Nasdaq Stock Market
    What is the current price of Contineum Therapeutics, Inc. - Common stock?
    The current price of Contineum Therapeutics, Inc. - Common stock is 14.61
    When was Contineum Therapeutics, Inc. - Common stock last traded?
    The last trade of Contineum Therapeutics, Inc. - Common stock was at 08/17/26 01:16 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.